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Age and sex have been identified as predictors of outcome 
in malignant melanoma (MM). The aim of this multicen-
tre, cross-sectional study was to analyse the role of age 
and sex as explanatory variables for the diagnosis of thin 
MM. A total of 2,430 patients with MM were recruited. 
Cases of in situ (Tis) and T1 MM were more frequent than 
T2–T4 MM (56.26% vs. 43.74%). Breslow thickness in-
creased throughout decades of life (analysis of variance 
(ANOVA) p < 0.001), with a weak correlation between 
Breslow thickness and patient’s age (r   = 0.202, p < 0.001). 
Breslow thickness was significantly less in women (1.79 vs. 
2.38 mm, p = 0.0001). Binary logistic regression showed a 
significant (p < 0.001) odds ratio for age 0–29 years (1.18), 
and 30–59 years (1.16), and for women (1.09). Age and sex 
explained 3.64% of the variation observed in Tis–T1 fre-
quency (R2 = 0.0364). Age and sex appear to explain a low 
percentage of the variation in the early detection of MM. 
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Malignant melanoma (MM) diagnosed at early stage 
(Tis and T1) has been observed with increased frequency 
in recent decades (1, 2). This is partially explained by 
improvements in access to specialized care, and by the 
potential “overdiagnosis” of pigmented lesions (3); ho-
wever, other studies reporting increasing incidences of 
MM among all Breslow thickness categories conclude 
that this increasing incidence is not solely due to over-
diagnosis (4).
The influence of age and sex on the variation in early 
detection and diagnosis of thin MM has been analysed 
repeatedly over recent decades (5, 6). The current study 
involved subanalysis of the Trends in the Diagnosis of 
Malignant Melanoma (TEDIMEL) project, a 10-year, 
multicentre study analysing the role of healthcare 
provision and demographic determinants in the early 
detection of MM, the global results of which have been 
published recently (1). The aim of this analysis was to 
assess the potential role of demographic determinants, 
age and sex, and their weight in explaining variations 
in the diagnosis of patients with early-stage MM.
METHODS
A multicentre, cross-sectional study was conducted at 14 
hospitals in the Public Health System of Andalusia (PHSA), a 
region in southern Spain. Cases of primary in situ MM (Tis) 
or invasive cutaneous MM diagnosed between 1 January 
2000 and 31 December 2009 were included in the study after 
verifying that the MMs failed to meet the following exclusion 
criteria: second primary MM, lack of Breslow thickness in 
the pathology report, primary MM pathologically diagnosed 
but not excised at the participating centres (biopsy specimens 
referred for specialized diagnosis were excluded), and lack of 
valid demographic information. A complete methodology of the 
TEDIMEL project has been published elsewhere (1).
Demographic, and pathological study variables recorded 
included: age, sex, year of diagnosis, Breslow thickness, and 
T-stage as defined by the American Joint Committee on Cancer 
Tumor-Node-Metastasis (TNM) Melanoma Staging System, 7th 
edition (7). Tumours diagnosed as Tis and MMs with a Bres-
low thickness < 1 mm (T1) were grouped together (Tis–T1). 
Likewise, tumours with a Breslow thickness ≥ 1 mm (i.e. T2, 
T3 and T4) were also grouped and jointly analysed (T2–T4). 
This information, together with the demographic data (age, 
sex), were gathered from the pathology reports stored in the 
information systems of the participating pathology units. 
In a first descriptive phase, the primary outcomes assessed 
were the mean Breslow thickness, and the frequency of Tis–T1 
and T2–T4 MM in the 10-year series as a whole.
In a second analytical phase, the role of demographic variables 
(age and sex) in explaining variations in Breslow thickness, and 
in the proportion of Tis–T1 MMs was tested through bivariate and 
multivariate analyses with the calculation of odds ratios (ORs).
For statistical analysis, XLSTAT® 2014 for Mac® software (v. 
4.05 Addinsoft SARL) was used. For quantitative data, statistically 
significant differences were shown using Student’s t and ANOVA 
tests. For qualitative data, the χ2 test, and the χ2 test for linear 
trend were used to show significant differences. The direction and 
strength of the linear relationship between 2 quantitative variables 
were measured by the linear correlation coefficient “r”. For the 
multivariate analysis, logistic binary regression with the Hosmer-
Lemeshow test for goodness of fit was applied. The R2 Nagelkerke 
coefficient of determination was used to express the proportion of 
the total variance of the response variable explained by the inde-
pendent variables. The age was coded as a dummy dichotomous 
variable (0–29, 30–59 and ≥ 60 years). The results of the bivariate 
and multivariate analyses were expressed as ORs and correspon-
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ding 95% confidence intervals (95% CIs). All significance tests 
were 2-sided, and p < 0.05 was considered statistically significant.
RESULTS
A total of 2,430 patients with MM, for whom valid data 
was available, were recruited. A significant predomi-
nance of female patients was observed (54.65% female 
vs. 45.35% males), with a non-significant lower mean 
age for women (54.27 vs. 56.35 years; p = 0.005). As 
a whole, Tis–T1 MM cases were more frequent than 
T2–T4 MM (56.26% vs. 43.74%).
Breslow thickness increased progressively through-
out the decades of life, with a significantly higher 
mean Breslow thickness in patients aged ≥ 70 years 
(ANOVA p < 0.001) (Fig. 1). Correlation and simple 
regression analysis showed a very weak association 
between Breslow thickness and patient age (r = 0.202 
95% CI 0.163–0.241, p < 0.001), with age explaining 
4.05% of the Breslow thickness variation (R2 coef-
ficient  = 0.0405) (Fig. S11). Tis–T1 MM was more 
frequent in patients aged 0–29 years (70.73%), followed 
by patients aged 30–59 years (60.92%) and patients 
aged ≥ 60 years (48.19%) (p < 0.001). The ORs for 
identifying Tis–T1 stage were 1.12 (95% CI 1.07–1.18, 
p < 0.001) in patients aged 0–29 years, 1.12 (95% CI 
1.06–1.18, p < 0.005) in the 30–59 group, and 0.84 (95% 
CI 0.80–0.88, p < 0.01) in patients aged ≥ 60 years. 
The mean Breslow thickness of the series was sig-
nificantly lower in women than in men (1.79 mm vs. 
2.38 mm, p = 0.0001) (Fig. 2) with a difference in the 
median Breslow thickness between sex groups of 0.21 
mm (median Breslow thickness in women 0.79 mm 
vs. 1.00 in men). Tis–T1 tumours were more frequent 
in women than in men (54.65% vs. 45.35%, p = 0.001) 
with an OR of identifying a Tis–T1 in women of 1.10 
(95% CI 1.05–1.16, p = 0.001).
Binary logistic regression including age and sex for 
Tis–T1 as the reference category showed significant 
ORs for age 0–29 years (OR 1.18, 95% CI 1.12–1.24, 
p < 0.001), and 30–59 years (OR 1.16, 95% CI 1.10–
1.22, p < 0.001), and for women (OR 1.09, 95% CI 
1.04–1.15, p < 0.001) (Fig. 2). After adjustment by age 
group, a higher likelihood of having Tis–T1 MM was 
observed in women aged 30–59 years (OR 1.62, 95% 
CI 1.28–2.05, p < 0.001). No differences were observed 
as for the likelihood of having thin MM in the other 
age groups (0–29 years: OR 0.88, 95% CI 0.48–1.62, 
p = 0.68; 60–90 years: OR 1.16, 95% CI 0.91–1.48, 
p = 0.22). Based on the R2 coefficient, age, as a catego-
rical variable (0–29, 30–59 and ≥ 60 years), explained 
3.00% of the variability observed in the frequency of 
Tis–T1 MM (R2 coefficient = 0.030), and sex explained 
0.80% of this variation (R2 coefficient = 0.008). These 
variables, age and sex together, explained 3.64% of the 
variability observed in Tis–T1 frequency (R2 = 0.0364).
DISCUSSION
This 10-year cross-sectional study including 2,430 
patients with MM has revealed a 9.3% increased fre-
quency of Tis–T1 MM in women (54.65% vs. 45.35%), 
and a difference of 0.58 mm in the mean Breslow 
thickness between women and men. This advantage 
in the detection of early MM was also observed in 
middle-aged patients. The differences found in these 
endpoints were all statistically significant in both the 
descriptive and analytical phases. Likewise, the ORs 
and correlation coefficient calculated also supported 
the advantage in early diagnosis observed for women 
and middle-aged patients. These results are in line with 
previous reports in which the detection of thin MM is 
partially determined by the age and sex of the patients 
(8, 9). Swetter et al. (8) found a higher frequency of 
thinner tumours (≤ 1 mm) in patients younger than 60 
years and in women, an advantage that is explained by 
improved self-detection behaviours and habits. Mer-
vic et al. (5) also described a higher median tumour 
thickness in middle-aged male patients compared with 
female patients in the same age group (0.83 vs. 0.75 
Fig. 2. Forest plot representation of the resulting binary logistic regression 
odds ratios of detecting a Tis-T1 malignant melanoma for the explanatory 
variables “age group” (as dummy variable) and “sex”.
Fig. 1. Mean and median Breslow thickness distribution by decades of life.
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mm, p < 0.001), a difference that was not significant in 
the older patient group (1.04 vs. 1.00 mm, p = 0.47).
However, a more careful assessment of statistics that 
provide information on the strength of the associations 
observed and to what extent the independent variables 
explain variations in the primary outcomes (Breslow 
thickness and T-stage) is warranted. In this study, even 
though both the “r” coefficient, and the R2 coefficient of 
determination support a significant and direct association 
between variables, the strength of the associations, as 
shown by the magnitude of these statistics, is weak. Both 
age and sex, analysed separately, served to explain 3% 
and less than 1% of the variation in the response variab-
les, respectively. Taken together, both predictor variables 
explained just 3.64% of the variation in the proportion 
of Tis–T1 MM. In other words, sex and age failed to 
explain 96% of the variation observed in the response 
variables. Thus, despite the statistically significant ORs 
and correlation coefficient observed, the weakness of the 
associations should prevent us from referring to age and 
sex as independent predictors of the response variable, 
but instead as partial reasons for its variation. More-
over, the inclusion of these statistics in studies aimed 
at identifying predictor or determinant factors would 
help to diminish the possibility of overestimations of the 
real effects of explanatory variables, which might also 
influence prevention strategies. In this regard, Goldberg 
et al. (10) analysed the screening data of patients with 
MM to identify factors associated with MM detection, 
and thereby derive a model of increased likelihood 
for MM detection through visual skin examinations 
at screenings. Among the factors that independently 
increased the likelihood of suspected MM, age over 50 
years (OR 1.2; 95% CI 1.1–1.3) and male sex (OR 1.4; 
95% CI 1.3–1.5) were identified (10). This result led the 
authors to conclude that refocusing efforts on providing 
a complete skin examination to those individuals with 
multiple risk factors (i.e. men and patients older than 50 
years) has the potential to increase yields for suspected 
MM and, consequently, to enhance early detection of 
MM (10). In this case, the ORs obtained reached the 
threshold for statistical significance, but no data was 
provided about the extent to which age and sex explain 
the likelihood of suspected MM.
The primary methodological limitation of this study 
is its retrospective nature. A second potential limitation 
relates to the study endpoints assessed and the lack of a 
survival analysis. However, the TEDIMEL project was 
not focused on recurrence or mortality outcomes, but on 
Breslow thickness and T-stage, both considered proxy 
markers of initial prognosis. In this regard, Breslow 
thickness and T-stage are still considered the strongest 
predictors of survival in patients with primary MM with 
no metastatic disease (1).
In conclusion, early diagnosis of MM is the mul-
tifactorial result of demographic, socioeconomic and 
healthcare provision determinants. Although age and 
sex demonstrate an association with the early detection 
of MM, the burden of thin MM (Tis–T1) explained by 
demographic factors is too low to accept them as major 
determinants of this outcome.
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